A Drug-drug Interaction Study of Avapritinib and Midazolam
A Drug-drug Interaction Study to Investigate the Effect of Avapritinib on the Pharmacokinetics of Midazolam in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST) and Other Advanced Solid Tumors
Sponsor: Blueprint Medicines Corporation
Listed as NCT04908176, this PHASE1 trial focuses on GIST and Gastrointestinal Stromal Tumors and remains completed. Sponsored by Blueprint Medicines Corporation, it has been updated 9 times since 2022, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Jan 2025 — Present [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Sep 2024 — Jan 2025 [monthly]
Active Not Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1
Status: Completed → Active Not Recruiting
-
May 2024 — Jul 2024 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Apr 2023 — May 2024 [monthly]
Recruiting PHASE1
▶ Show 4 earlier versions
-
Mar 2023 — Apr 2023 [monthly]
Recruiting PHASE1
-
Sep 2022 — Mar 2023 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Apr 2022 — Sep 2022 [monthly]
Not Yet Recruiting PHASE1
-
Sep 2021 — Apr 2022 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Blueprint Medicines Corporation
For direct contact, visit the study record on ClinicalTrials.gov .